BAT's 2023 Financial Report: New Categories Drive Revenue Growth

BAT by 2FIRSTS.ai
Feb.09.2024
BAT's 2023 Financial Report: New Categories Drive Revenue Growth
BAT Releases 2023 Financial Report: Non-combustible category revenue now accounts for 16.5% of group revenue, increasing 170 basis points from 2022.

British American Tobacco (BAT) released its financial report for the year 2023 on February 8. The report highlights the robust sales of Vuse and Velo, which have driven the revenue growth in new categories including vaporization, heat-not-burn (HNB), and oral products. The income from non-combustible categories now accounts for 16.5% of the group's total revenue, representing an increase of 170 basis points compared to the fiscal year 2022.

 

Other key points are as follows:

 

The conglomerate's revenue has decreased by 1.3%, with an organic growth of 3.1% (measured at constant exchange rates), driven by a significant increase of 21.0% in organic revenue from new categories.

 

A new category, including atomized, HNB, and oral products, achieved profitability in 2023, surpassing the original goal by two years. This led to an increase in the group's profits by £398 million.

 

The conglomerate has reached a global settlement with Philip Morris International (PMI), resolving all ongoing patent infringement lawsuits between the two parties in relation to heated products (HP) and aerosol products.

 

The overall revenue for combustible products witnessed a marginal increase of 0.6%, while the organic price/composition experienced a positive growth of +6.1%. However, due to the macroeconomic pressures in the United States, there was a decline in total sales, specifically in the high-end market segment, affecting both geographic composition and sales volume.

 

AME (America and Europe Market) and APMEA (Asia Pacific Middle East Market) have demonstrated strong performance. The report shows that the new categories, including aerosol, heat-not-burn, and oral products, have achieved profits of 1.67 billion pounds and 610 million pounds respectively in these two markets.

 

The reported operating loss amounted to £15.751 billion (with a decline of 95.8 percentage points in the reported operating profit margin, reaching -57.7%), primarily influenced by a non-cash impairment charge of £27.6 billion associated with the US operations (£273 billion).

 

Adjusted organic operating profit increased by 3.9% at constant exchange rates, while the adjusted organic operating profit margin rose by 40 basis points to reach 45.6%.

 

According to the report, the diluted earnings per share amounted to -646.6 pence. However, after adjusting for organic factors, the diluted earnings per share saw a growth of 5.2% at a constant exchange rate.

 

The operating cash flow conversion rate has reached 100%, indicating that the company efficiently converts its operating cash flow into positive cash flow. However, the adjusted net debt-to-EBITDA ratio has declined to 2.6 times, reflecting a decrease in the company's financial leverage after adjusting for organic factors.

 

The dividend has grown by 2.0% to 235.52 pence, in line with the gradual increase in dividends.

 

Sustained ESG Progress - MSCI Rating Upgraded to A Grade in 2023 (2022: BBB) Two Years Ahead of Schedule, Exceeding Water Consumption and Waste Generation Targets.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

FDA Renews Exposure Modification Authorization for IQOS Devices and Three HeatSticks Products
FDA Renews Exposure Modification Authorization for IQOS Devices and Three HeatSticks Products
U.S. Food and Drug Administration renewed modified risk granted orders for five IQOS products from Philip Morris Products S.A., including two IQOS system holders and chargers and three HeatSticks products. Under the renewed orders, the products may continue to be marketed with an exposure modification claim.
Apr.20 by 2FIRSTS.ai
Special Report|U.S.-Facing Retailer Lists RELX Creator Pro 15K: A Chinese Brand Signal Under FDA’s Lower-Priority Enforcement Window
Special Report|U.S.-Facing Retailer Lists RELX Creator Pro 15K: A Chinese Brand Signal Under FDA’s Lower-Priority Enforcement Window
Vapesourcing has listed RELX Creator Pro 15K as “Coming Soon” with U.S. warehouse shipping options; while the page does not show that RELX has entered the U.S. market through official channels or that the product has received FDA authorization, the listing suggests that Chinese brand-led ENDS products are becoming a new point of observation as the U.S. market reassesses regulatory risk following the FDA’s updated enforcement-priority policy.
Industry Insight
Jun.11
Belgium Approves Vape Flavor Ban, Allowing Only Tobacco-Flavored and Unflavored Products From September 2028
Belgium Approves Vape Flavor Ban, Allowing Only Tobacco-Flavored and Unflavored Products From September 2028
Belgium’s federal government on Thursday approved a ban on flavored vapes, allowing only tobacco-flavored and unflavored e-cigarettes on the market from September 2028. Health Minister Frank Vandenbroucke said the measure is aimed at protecting the health of children and young people and preventing a new generation from becoming dependent on tobacco.
May.06 by 2FIRSTS.ai
The new regulations on nicotine in Argentina are creating caution, expectations, and doubts about the market, according to a local reference in harm reduction for smoking.
The new regulations on nicotine in Argentina are creating caution, expectations, and doubts about the market, according to a local reference in harm reduction for smoking.
The new Argentine framework for tobacco and nicotine marks a shift from prohibition towards registration, traceability, and health surveillance. Juan Facundo Teme told 2Firsts that adult consumers and some of the commercial sector are cautiously optimistic, although concerns remain about flavors, registration costs, and market access.
May.11
WSJ: White House Pushes for More Flavored Vape Approvals as FDA Commissioner Makary Blocks Move
WSJ: White House Pushes for More Flavored Vape Approvals as FDA Commissioner Makary Blocks Move
According to The Wall Street Journal, the White House is pushing to allow more flavored vape products onto the market for the first time in years, but FDA Commissioner Marty Makary opposes the move and has blocked the plan. The report said a memo from Makary’s office prevented authorization of several flavors from vape maker Glas, even after FDA scientific reviewers had supported them.
Apr.20 by 2FIRSTS.ai
 FDA Begins Review of 22nd Century’s VLN MRTP Renewal Applications
FDA Begins Review of 22nd Century’s VLN MRTP Renewal Applications
The U.S. Food and Drug Administration (FDA) has initiated scientific review of renewal applications for 22nd Century Group’s VLN reduced-nicotine cigarettes under the Modified Risk Tobacco Product (MRTP) pathway, with current authorizations set to expire in December 2026.
News
May.13